医学
炎症性肠病
溃疡性结肠炎
胃肠病学
疾病
肾功能
肾脏疾病
内科学
病因学
免疫学
作者
Anmol Singh,Tejasvini Khanna,Diksha Mahendru,Jasraj Kahlon,Vikash Kumar,Aalam Sohal,Juliana Yang
出处
期刊:World journal of nephrology
[Baishideng Publishing Group Co (World Journal of Nephrology)]
日期:2024-09-19
卷期号:13 (3)
被引量:1
标识
DOI:10.5527/wjn.v13.i3.96574
摘要
Inflammatory bowel disease (IBD) is a chronic condition characterized by immune-mediated inflammation in the gastrointestinal tract, which follows a relapsing and remitting course. Apart from affecting the gastrointestinal tract, IBD also has extra-intestinal manifestations (EIMs). While the etiology of extraintestinal manifestation remains unclear, it is theorized to be based on immunological responses influenced by genetic factors. Renal involvement is one of the EIMs observed in ulcerative colitis and Crohn’s disease. The renal manifestations in IBD patients encompass a range of conditions including nephrolithiasis, amyloidosis, tubulointerstitial nephritis, glomerulonephritis (GN), obstructive pathologies, and chronic kidney disease (CKD). The incidence of CKD in IBD patients varies from 5%-15%. The decline in renal function can stem from various factors such as direct inflammatory damage to the kidneys leading to glomerular or tubular injury, or from complications like recurrent stones, amyloidosis, or GN. Additionally, nephrotoxic medications used in treating IBD, such as TNF-α inhibitors, calcineurin inhibitors, and aminosalicylates, can exacerbate the decline in renal function. Currently, there is a lack of consensus regarding these patients' screening and renal function monitoring. This review aims to assess the existing literature on the different renal complications among individuals with IBD, shedding light on their pathophysiology and management.
科研通智能强力驱动
Strongly Powered by AbleSci AI